BAGE2
B melanoma antigen 2
Also known as: BAGE2_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for BAGE2 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
109 residues, UniProt reviewed canonical sequence.
>Q86Y30|BAGE2
1 MAAGVVFLAL SAQLLQARLM KEESPVVSWR LEPEDGTALD VHFVSTLEPL SNAVKRNVPR
61 CIIILVLQEP TAFRISVTSS CFVQNTLTKL LKDRRKMQTV QCATARETSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BAGE2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.46
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BAGE2 as an antibody target. Whether an autoantibody or antibody against BAGE2 could matter depends on whether native BAGE2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BAGE2 is annotated as secreted, so native BAGE2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label BAGE2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...